Neurogene (NASDAQ:NGNE) Earns “Outperform” Rating from William Blair

Neurogene (NASDAQ:NGNE)‘s stock had its “outperform” rating reiterated by investment analysts at William Blair in a report issued on Tuesday,RTT News reports.

A number of other research firms have also recently weighed in on NGNE. Robert W. Baird boosted their price objective on shares of Neurogene from $54.00 to $72.00 and gave the company an “outperform” rating in a research report on Tuesday, November 12th. Leerink Partners increased their price objective on shares of Neurogene from $45.00 to $72.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 12th. Stifel Nicolaus boosted their target price on Neurogene from $44.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of Neurogene in a report on Tuesday. Finally, BMO Capital Markets reduced their price target on shares of Neurogene from $65.00 to $60.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $60.83.

Neurogene Trading Down 11.0 %

Shares of Neurogene stock opened at $15.33 on Tuesday. The stock has a 50 day moving average price of $45.90 and a 200-day moving average price of $39.79. Neurogene has a one year low of $12.49 and a one year high of $74.49.

Institutional Investors Weigh In On Neurogene

A number of hedge funds have recently made changes to their positions in NGNE. RTW Investments LP boosted its stake in Neurogene by 6.0% in the third quarter. RTW Investments LP now owns 1,135,256 shares of the company’s stock valued at $47,635,000 after acquiring an additional 64,691 shares in the last quarter. FMR LLC increased its holdings in shares of Neurogene by 912.4% in the third quarter. FMR LLC now owns 731,801 shares of the company’s stock valued at $30,706,000 after purchasing an additional 659,515 shares during the period. Vanguard Group Inc. raised its position in Neurogene by 906.5% during the 1st quarter. Vanguard Group Inc. now owns 507,483 shares of the company’s stock worth $25,831,000 after buying an additional 457,062 shares during the last quarter. Baker BROS. Advisors LP lifted its stake in Neurogene by 0.6% during the 1st quarter. Baker BROS. Advisors LP now owns 456,015 shares of the company’s stock valued at $23,211,000 after acquiring an additional 2,499 shares during the period. Finally, State Street Corp boosted its holdings in shares of Neurogene by 17.5% in the 3rd quarter. State Street Corp now owns 246,540 shares of the company’s stock valued at $10,345,000 after acquiring an additional 36,687 shares during the last quarter. 52.37% of the stock is currently owned by hedge funds and other institutional investors.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.